Best GLP-1 for Seniors: Safest Options, Real Costs, Medicare, and Top Programs

We compared major GLP-1 access paths for adults 60+ — brand-name through your doctor, Medicare's new Bridge program, telehealth programs, and compounded options — focusing on pricing transparency, clinical oversight, senior-specific safety concerns, drug interaction screening, and cancellation terms. Here's what we found.

Quick Decision Guide

What's the Best GLP-1 Medication for Seniors Right Now?

There isn't one best GLP-1 for every senior — and anyone who tells you otherwise is selling something. What there is is a best fit for your situation based on four things: your health conditions, your coverage, your tolerance for injections, and your budget.

Here's how the major GLP-1 medications stack up for adults over 60:

Sources: FDA prescribing information for Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, Foundayo. Clinical data from STEP, SURMOUNT, and SELECT trials published in the New England Journal of Medicine.

Which GLP-1 Is Best for YOUR Situation?

We know you didn't come here for a lecture. You came here because something specific is going on — a doctor's recommendation, a friend's transformation, or a number on the scale that's affecting your knees, your blood sugar, or your confidence. So let's cut straight to it.

If You Have Type 2 Diabetes

You're in the strongest position of anyone reading this page. GLP-1 medications were originally designed for type 2 diabetes, and both semaglutide (Ozempic/Rybelsus) and tirzepatide (Mounjaro) are FDA-approved for it. That means:

• Your insurance or Medicare Part D is far more likely to cover it
• You get the dual benefit: better A1C and weight loss
• Your doctor already has a clinical reason to prescribe it

If You Have Heart Disease or High Cardiovascular Risk

This is where the science gets genuinely exciting for older adults. The SELECT trial (published in the New England Journal of Medicine in 2023) studied over 17,600 adults with obesity and established cardiovascular disease. The mean age of participants was 61.6 years. The result: semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke — by 20% over a mean follow-up of 39.8 months.

That's not just a weight loss finding. That's a cardiovascular protection finding. And in March 2024, the FDA approved Wegovy specifically for cardiovascular risk reduction in adults with obesity or overweight and established heart disease.

If You're on Medicare or a Fixed Income

Let's be direct about the money, because we know it matters — and because the rules just changed in your favor.

What Medicare covers right now (June 2026):

• GLP-1 medications for type 2 diabetes — yes, Medicare Part D covers Ozempic, Mounjaro, and Rybelsus
• GLP-1 medications for cardiovascular risk reduction (Wegovy with the CV indication) — yes, for eligible patients
• Zepbound for obstructive sleep apnea — yes, Part D plans can cover it under the OSA indication
• GLP-1 medications for weight loss alone — not yet, but that changes July 1

If you don't qualify, can't wait, or want to skip the paperwork entirely:

We include the Bridge at the top of this table because we'd rather point you to Medicare than to any affiliate on this page. The cash-pay programs below are for everyone the Bridge leaves out.

If You Want a Pill (or Gum) Instead of a Shot

Good news: you have more needle-free options than ever — three real paths now.

Wegovy tablets received FDA approval in late 2025 and became available in U.S. pharmacies in January 2026. They're approved for the same indications as Wegovy injection — weight management and cardiovascular risk reduction — self-pay from $149/month at lower doses, and covered by the Medicare Bridge at $50/month for qualifiers starting July 1.

Rybelsus (oral semaglutide) has been available for type 2 diabetes since 2019. It's a once-daily tablet taken on an empty stomach with a small sip of water, then you wait at least 30 minutes before eating, drinking, or taking other medications — a timing rule that matters if you take several morning pills.

Embody's GLP-1 gum is the newest needle-free path: one piece of compounded semaglutide or tirzepatide gum per day, prescribed by a licensed clinician when appropriate — $149 the first month for semaglutide gum, then $349/month. No needles, no pen to handle. Two honest notes for seniors: the gum is a compounded product (not FDA-approved), and if you wear dentures or have jaw issues, ask the clinician during intake whether this format makes sense for you.

MEDVi also offers a compounded oral dissolvable tablet starting at $249/first month.

If Your Adult Child Is Researching This for You

First — good for them, and good for you. Here's what to look for in a GLP-1 program for your parent:

• Does the provider screen for drug interactions? Your parent is likely on multiple medications. A provider that doesn't ask about current prescriptions is a red flag.
• Is there clinician-level oversight? Not just a chatbot or algorithm — a licensed clinician reviewing the case who can say no.
• Can they cancel easily — and what happens if they don't qualify? Seniors don't want to feel trapped in a subscription. Embody refunds the full payment if its clinician disqualifies your parent for a medical reason — that's the strongest try-it policy on this list.
• Is pricing transparent? No hidden fees, no bait-and-switch between intro and refill pricing. We print both numbers for every provider on this page.

Is GLP-1 Safe for Seniors? What the Clinical Data Actually Shows

This is the question that keeps most seniors on the fence. So let's answer it clearly.

Yes — GLP-1 medications are generally considered safe for adults over 60, and clinical trials have specifically included older adults. The FDA has not set an upper age limit for semaglutide or tirzepatide. In the Wegovy prescribing information, the FDA notes:

• Injection weight-management trials: 9% were 65–<75 years old; 1% were 75+
• Tablets weight-management trial: 8% were 65–<75; 2% were 75+
• CV outcomes trial (SELECT): 30% were 65–75; 8% were 75+

No overall differences in safety or efficacy were observed compared to younger adults — though the FDA adds that "increased sensitivity in some geriatric individuals cannot be ruled out." The SELECT trial provides particularly strong evidence because nearly 40% of participants were 65 or older.

Source: Wegovy FDA prescribing information (2024 revision); Lincoff AM et al., NEJM 2023; 389:2221-2232.

Side Effects Seniors Should Watch For

These are the same side effects that affect all GLP-1 users — but some hit harder when you're older:

Common (and usually manageable):

• Nausea, vomiting, diarrhea — Usually worst during the first few weeks and during dose increases. For seniors, the bigger risk is dehydration. Stay ahead of fluids.
• Constipation — Common across all ages. Adequate fiber, hydration, and gentle activity usually help.
• Decreased appetite — This is the mechanism working. But for seniors, eating too little is a real risk. You still need adequate protein and calories even when you're not hungry.

Less common but important:

• Hypoglycemia — Particularly if you're on insulin or sulfonylureas for diabetes. Your provider should adjust your diabetes medications when starting a GLP-1.
• Gallbladder issues — Slightly elevated risk of gallstones, especially with rapid weight loss. Report any severe upper abdominal pain.
• Pancreatitis — Rare but serious. Severe, persistent abdominal pain that radiates to the back needs immediate medical attention.
• Hip and pelvis fractures — In the SELECT cardiovascular outcomes trial, the Wegovy prescribing information notes that patients 75 and older reported more hip and pelvis fractures on Wegovy than placebo. This is important data and one reason why bone health monitoring matters.

Sources: FDA prescribing information for Wegovy (2024), Ozempic, Zepbound, Mounjaro; Novo Nordisk novoMEDLINK geriatric safety data.

Drug Interactions Seniors Need to Discuss

If you're over 60, there's a decent chance you're taking more than one medication. GLP-1s slow gastric emptying — meaning they change how quickly your stomach processes what you put in it, including other pills. Here's what to flag with your provider:

• Insulin or sulfonylureas: Hypoglycemia risk increases. Your provider should reduce the dose of these medications when starting a GLP-1.
• Blood thinners (warfarin): GLP-1s may affect absorption timing. Your INR should be monitored more closely during the first few months.
• Blood pressure medications: As you lose weight, your blood pressure often drops. You may need less medication, not more. If you get dizzy standing up, tell your doctor.
• Thyroid medication (levothyroxine): Delayed gastric emptying can affect absorption. Maintain your regular dosing routine and get your thyroid levels checked.
• Oral medications taken on an empty stomach: The timing of all oral medications may need review.

This is exactly why we rank providers on drug interaction screening. If a GLP-1 provider doesn't ask what else you're taking during intake, that's not a provider built for seniors. Walk away. For more details, see our safe usage guide.

Is There an Age Limit for GLP-1 Medications?

No. There is no FDA-imposed upper age limit for semaglutide (Wegovy, Ozempic, Rybelsus) or tirzepatide (Zepbound, Mounjaro).

What does matter is your individual health status. Your doctor evaluates kidney function, nutritional status, frailty, current medications, and bone density — not a number on your driver's license. A healthy 72-year-old with obesity and high blood pressure is a completely appropriate candidate. An 85-year-old who's frail and losing weight unintentionally is probably not.

Source: FDA prescribing information, geriatric use sections for Wegovy, Ozempic, Zepbound, Mounjaro.

Will GLP-1 Cause Muscle Loss? A Senior's Guide to Staying Strong

We're going to be straight with you about something most GLP-1 websites won't touch.

GLP-1 medications can cause muscle loss alongside fat loss. In the STEP trials, roughly 39% of the total weight lost was lean mass (which includes muscle). For a 35-year-old with plenty of muscle to spare, that's a footnote. For a 65-year-old who's already losing muscle naturally — a process called sarcopenia — it matters.

A review published in Pharmacotherapy (2024) on pharmacological treatment of obesity in older adults emphasized that weight-loss interventions in this population should include exercise and adequate protein to preserve muscle and bone. The American Geriatrics Society and AACE/ACE guidelines echo this: evaluate for sarcopenia before and during treatment, and build a preservation plan.

Source: "Pharmacological Treatment of Obesity in Older Adults," PMC (2024); AACE/ACE Obesity Clinical Practice Guidelines. See also: How to prevent muscle loss on GLP-1.

The Senior Muscle Preservation Protocol

This isn't complicated. It just has to be deliberate.

If your GLP-1 provider doesn't discuss protein and exercise with you, they're not treating seniors properly. This is one of the reasons we prioritize clinical supervision in our rankings — a good provider builds a preservation plan alongside the prescription.

GLP-1 Provider Comparison for Seniors (2026)

Now let's talk about where to actually get GLP-1 medication if you're 60+ and paying cash. We evaluated providers on what matters most for seniors: medical supervision quality, drug interaction screening, pricing transparency, refund and cancellation terms, and regulatory standing.

Full Provider Comparison Table (Senior-Weighted)

Embody and MEDVi pricing and review data verified June 2026; TrimRx, Yucca Health, and Willow last verified February 2026 — confirm current pricing on each provider's site before purchasing. Use our pricing index for the latest.

Embody — Best Low-Cost Start for Cash-Pay Seniors (and the Only Needle-Free Gum)

We moved Embody to the front of the cash-pay lane for three reasons that matter specifically when you're 60+: it costs the least to find out if this treatment is right for you, it has the strongest refund policy on this list, and it's the only program offering a GLP-1 you don't inject and don't have to schedule around an empty stomach.

What it costs (verified June 2026):

• Compounded semaglutide injection: $99 first month, then $299/month (flat-pricing plans listed from $199/month)
• Needle-free GLP-1 gum: $149 first month (semaglutide), then $349/month
• Compounded tirzepatide injection: $149 first month, then $399/month
• HSA/FSA cards accepted; cash-pay only — Embody does not bill commercial insurance, Medicare, or Medicaid

What you get:

• Licensed-clinician review of your health history and current medications, typically within 24 hours of intake
• Weekly injection or daily gum — your clinician helps decide which format fits
• 24/7 care-team messaging and ongoing dose adjustments
• Fast, temperature-controlled shipping if a provider approves treatment
• U.S.-based 503A compounding pharmacies
• A full refund if the clinician determines you're not medically eligible — the cost of finding out is protected

The one thing you should know first: Embody does not have a long public track record. Its Trustpilot profile shows a 3.1/5 rating from just 82 reviews as of June 2026 — a small, mixed early sample — and the most common complaints involve refill shipping delays and billing friction. If a 10,000-review history is what lets you sleep at night, MEDVi is the better pick, and we say so plainly. But because Embody is the newer, leaner program, it does what the established players don't: the lowest first month on this list, the only gum format anywhere, and a refund if you don't qualify. For a senior on a fixed income, that combination means you can find out whether GLP-1 therapy suits you for $99 — risk-protected — instead of $179 or more.

Practical senior tips if you choose Embody: Order refills a week early so a shipping delay never leaves you skipping a dose; confirm your state during intake (Embody's FAQ currently lists Mississippi and Louisiana as unavailable); and if you wear dentures, ask the clinician whether the gum format or the injection makes more sense.

The honest downside: Embody's shipped options are compounded GLP-1 medications — not FDA-approved finished drugs. No insurance or Medicare billing of any kind. Ongoing pricing steps up from the $99 first month to $299/month, so budget for the refill rate. Prices, pharmacy availability, and state eligibility can change and should be confirmed during intake.

MEDVi — Most Established Cash-Pay Program (Largest Review Base)

MEDVi held the top spot on this page from February through May, and the reasons it ranked first still matter: documented physician oversight, transparent all-in pricing, and the largest independent review base in cash-pay GLP-1 care — 4.4/5 from 11,498 Trustpilot reviews as of June 2026.

What it costs (verified June 2026):

• First month: $179 (includes physician review, personalized plan, metabolic report, medication, and shipping)
• Monthly refills: $299/month
• Oral dissolvable tablets: $249/first month (refill pricing varies)
• No contract, no hidden membership fees — month-to-month

What you get:

• Licensed physician review of your health history and current medications (through OpenLoop Health's provider network)
• Compounded semaglutide (weekly injection or daily dissolvable tablet)
• Personalized care plan, unlimited appointments, 24/7 support access via messaging
• Medication shipped to your door (MEDVi states shipping is included in all plans)

Why it works for seniors: The physician-supervised model with unlimited appointments is what separates MEDVi from bare-bones discount providers — for seniors on multiple medications, that access matters. And the review volume means you can read thousands of real patient experiences before spending a dollar.

The honest downside: MEDVi is cash-pay — no insurance or Medicare. The intro-to-refill jump ($179 → $299) is a $120/month increase you should budget for. The entry price is $80 higher than Embody's for the same $299 ongoing rate.

What real patients say: One Trustpilot reviewer noted: "The doctors are accessible! Online medication management can feel scary, but they are careful." Another shared a more mixed experience, noting a wait time of about 10 days for an initial appointment — a reminder that telehealth isn't always instant. On ConsumerAffairs, one user reported meaningful weight loss results, going from 158 to 138 pounds, crediting the appetite reduction effect.

Individual results vary. These reviews are shared from third-party platforms (Trustpilot, ConsumerAffairs) to illustrate real patient perspectives, not to guarantee outcomes.

TrimRx — Best Value for Semaglutide (Stable Pricing)

TrimRx stands out for a simple reason: $199/month for compounded semaglutide, all-inclusive, with no price increases as your dose goes up. For seniors who want predictable costs month over month, this matters.

What it costs (verified February 2026):

• Compounded semaglutide: $199/month (all doses)
• Compounded tirzepatide: $349/month (all doses)
• All-inclusive: consultation, medication, supplies, shipping, and follow-up appointments

Why it works for seniors: No membership fee on top of medication cost. The flat pricing means your month-3 cost is the same as your month-1 cost — no surprise jumps. Licensed providers conduct medical evaluations, and the program includes ongoing follow-up appointments. Read our full TrimRx review.

The honest downside: TrimRx is newer to the market compared to some competitors, and the level of ongoing support is lighter than Embody's 24/7 messaging or MEDVi's unlimited appointments. We've also seen billing and cancellation complaints in reviews — read the cancellation terms before starting.

Yucca Health — Best Long-Term Plan Pricing

Yucca Health offers some of the lowest per-month pricing in the market — especially on their 6-month plans, where compounded semaglutide drops to approximately $146/month. No membership fee on top of that.

What it costs (verified February 2026):

• Compounded semaglutide: pricing varies by plan length (~$146/mo on 6-month plan; higher on monthly plans)
• Compounded tirzepatide: available (pricing varies)
• No membership fee — medication cost is the total cost
• UPS 2-Day Air shipping included

Why it works for seniors: Yucca's provider review process is thorough — a licensed U.S. provider reviews your intake within 24 hours, and they follow a structured titration schedule designed to minimize side effects. Over 20,000 patients on their platform, with a Trustpilot average around 4.5/5 from 500+ reviews.

The honest downside: The ~$146/month price requires committing to a 6-month plan upfront — a bigger initial outlay than month-to-month programs. Only consider this after you know you tolerate the medication. Start month-to-month elsewhere (Embody's $99 first month is the cheapest trial), then move to Yucca's bundle pricing once you know GLP-1 therapy works for you.

Willow — Premium All-Inclusive Option

Willow is a higher-priced option, but it's truly all-inclusive — $299+/month covers everything: medication, physician-designed treatment plan, same-day prescriptions, free 2-day shipping, and ongoing clinician support through your patient portal.

What it costs (verified February 2026):

• Compounded semaglutide (injection or oral): $299/month
• Compounded tirzepatide: $399+/month
• All-inclusive: no hidden fees, no separate membership charges

Why it works for seniors: Willow's physician team designs personalized treatment plans and offers same-day prescription processing. Direct messaging to your physician via the patient portal. LegitScript-certified. Optional ondansetron ($30/mo) for nausea management.

The honest downside: At $299+/month, Willow is the most expensive compounded option on this list, and it's only available in 33 states. Willow was also named in the FDA's March 2026 warning-letter wave over compounded-GLP-1 marketing claims.

The Brand-Name Route: When to Go Through Your Doctor

If any of the following apply to you, your doctor is the right first step — not a telehealth program:

• You have Medicare Part D and type 2 diabetes — Ozempic, Mounjaro, and Rybelsus are covered today. Start with your doctor.
• You have cardiovascular disease and obesity — Wegovy may be covered under the cardiovascular indication, today. Ask your cardiologist.
• You qualify for the Medicare GLP-1 Bridge (opens July 1, 2026) — BMI 35+, or BMI 27+ with a condition like hypertension, prediabetes, heart failure, chronic kidney disease, or cardiovascular disease, plus enrollment in a Part D or MA-PD plan. That's brand-name Wegovy, Zepbound KwikPen, or Foundayo at $50/month. Call your doctor's office this month so the prior authorization is ready at launch.
• You have a complex medical history or take 5+ medications — An in-person evaluation with an endocrinologist or obesity medicine specialist gives you a higher level of clinical oversight. You can always transfer to telehealth for ongoing refills.
• Your private insurance covers brand-name GLP-1s — Some employer plans and Medicare Advantage plans cover Wegovy or Zepbound. Check your formulary first.

We include this section because we'd rather lose an affiliate commission than send you down the wrong path. If brand-name coverage is available to you, use it.

Compounded GLP-1 for Seniors: What You Need to Know

If you're considering a telehealth program that prescribes compounded semaglutide, you should understand what "compounded" means — and what it doesn't.

• What compounded semaglutide is: A compounded medication containing semaglutide, prepared by a licensed compounding pharmacy pursuant to a prescription. It is not FDA-approved. These pharmacies are regulated by state boards of pharmacy and, in the case of 503B outsourcing facilities, by the FDA.
• What it's not: It is not FDA-approved as a finished product. Compounded formulations have not been reviewed by the FDA for safety, effectiveness, or quality before marketing, and they are not the same as generic drugs.
• What the FDA has said: The FDA sent warning letters in 2025–2026 to companies making misleading claims about compounded semaglutide and tirzepatide — including a February 2026 letter to MEDVi and a March 2026 letter to Willow. This doesn't mean all compounded semaglutide is unsafe — it means you need to choose your source carefully.

When Should a Senior NOT Take GLP-1 Medication?

No medication is right for everyone, and GLP-1s are no exception. For a detailed list, see our GLP-1 contraindications guide.

Absolute contraindications (do not take):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to semaglutide or tirzepatide

Situations where GLP-1 may not be appropriate for seniors:

• You're significantly underweight or losing weight unintentionally
• You have severe gastroparesis (GLP-1s slow gastric emptying further)
• You have a history of pancreatitis
• You're frail, malnourished, or have advanced sarcopenia
• You have end-stage kidney disease (dosing adjustments and close monitoring are necessary)

How GLP-1s Interact with Common Senior Health Conditions

GLP-1 and Type 2 Diabetes

The dual benefit here is undeniable. GLP-1s lower A1C and promote weight loss — both of which are foundational goals for managing type 2 diabetes in older adults. The American Diabetes Association's Standards of Care include GLP-1 receptor agonists as a preferred second-line therapy for T2D, particularly in patients with established cardiovascular disease or at high cardiovascular risk.

If you have diabetes, you likely already qualify for insurance or Medicare coverage. Start there.

Source: American Diabetes Association Standards of Care (2025).

GLP-1 and Heart Disease

The SELECT trial is worth repeating. In adults 45 and older with obesity, overweight, and established cardiovascular disease (but no diabetes), semaglutide reduced major adverse cardiovascular events (MACE) by 20%. Risk reductions were consistent across different ages, sexes, and ethnicities. The mean follow-up was nearly 40 months — this isn't short-term data.

For seniors with heart disease, GLP-1 medication may be protective, not just a weight-loss tool.

Source: Lincoff AM et al., NEJM 2023; ACC SELECT trial summary; Cleveland Clinic SELECT trial press release (2023).

GLP-1 and Joint Pain

This is the benefit seniors report most passionately. Every pound of body weight puts roughly 4 pounds of pressure on your knees. Losing 30 pounds takes 120 pounds of force off your joints. Many seniors on GLP-1 therapy report meaningful improvements in mobility — walking farther, climbing stairs with less pain, and in some cases, delaying or avoiding joint replacement surgery.

GLP-1 and Kidney Function

Early data from the FLOW trial (semaglutide) suggests kidney-protective effects in patients with type 2 diabetes and chronic kidney disease. For seniors with compromised kidney function, dosing adjustments may be necessary — your provider should check your eGFR (estimated glomerular filtration rate) before starting treatment and monitor it periodically.

Source: FLOW trial data; FDA prescribing information regarding renal impairment.

GLP-1 and Bone Health

This is an area of active research and one where the data isn't fully settled. The Wegovy prescribing information notes that in the cardiovascular outcomes trial, patients 75 and older reported more hip and pelvis fractures on Wegovy than placebo. Weight loss of any kind can affect bone density, and seniors are already at higher osteoporosis risk.

Source: Wegovy FDA prescribing information (2024 revision), geriatric use and fracture data.

How We Evaluated GLP-1 Programs for Seniors

We want you to know exactly how we made these rankings — because trust is the entire point.

What we evaluated (weighted for seniors):

What we checked: Provider websites, pricing pages, terms of service, pharmacy partner credentials, patient reviews on Trustpilot and ConsumerAffairs, FDA warning-letter publications, and clinical team disclosures. Embody and MEDVi were fully re-verified in June 2026; rankings changed as a result, and we said so at the top of the page.

What we did NOT do: We did not receive free product or preferential treatment from any provider. Our rankings reflect independent evaluation. We earn a commission if you sign up through our links, but a provider's affiliate relationship does not influence where they appear in our rankings — their performance on the criteria above does.

Our verification process: We re-check pricing and policies regularly and update "Last Verified" dates accordingly. When a claim comes from the provider's own website, we label it "provider-stated." When we can independently confirm it, we say "verified." Read our full methodology.

Edge Cases: The Questions That Send Seniors Back to Search

These are the specific scenarios that cause people to leave a page and keep searching. We'd rather answer them here.

"I'm on Medicare Advantage — Is That Different from Part D?"

For the GLP-1 Bridge, the good news is: both work. The Bridge is open to beneficiaries enrolled in a standalone Prescription Drug Plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD) in 2026 — including certain Special Needs Plans and dually eligible beneficiaries. Outside the Bridge, many MA plans already cover GLP-1s for qualifying diagnoses (diabetes, cardiovascular risk, sleep apnea) with varying copays. Call the number on your Medicare Advantage card and ask: "Do you cover semaglutide or tirzepatide, and under what diagnoses?"

"I Travel or Snowbird — Can I Get Refills in Another State?"

Telehealth programs operate in most U.S. states, but licensing rules vary. Before you leave for the winter, confirm with your provider that they can prescribe and ship to your destination state (Embody, for example, currently excludes Mississippi and Louisiana per its FAQ). Brand-name prescriptions from your local doctor can typically be filled at any pharmacy nationwide — one more point for the Bridge route if you qualify.

For injectable medications, plan your travel around your supply. Most GLP-1 injections are weekly, so make sure you have enough for your trip plus a buffer. Carry medications in a cooler bag during travel, and never store them in a hot car.

"What If I Miss a Dose?"

Missed-dose rules differ by medication — don't assume one rule fits all:

Wegovy/Ozempic (semaglutide) injection: If you miss a dose and there are at least 2 days (48 hours) until your next scheduled dose, take it as soon as you remember. If fewer than 2 days remain, skip it and resume your normal schedule. Don't double up. (Source: Wegovy FDA prescribing information)

Zepbound/Mounjaro (tirzepatide) injection: Take your missed dose as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip it and take your next dose on the regularly scheduled day. (Source: Zepbound prescribing information, Eli Lilly)

Daily oral medications (Rybelsus, Wegovy tablets) and daily gum formats: Skip it and take the next one at your regular time the following day.

Missing an occasional dose isn't a crisis. Missing multiple weeks is more concerning — talk to your provider about whether you need to re-titrate from a lower dose. (This is also why we suggest ordering refills a week early with any shipped program.)

"Can I Switch from Semaglutide to Tirzepatide (or Vice Versa)?"

Yes, with your provider's guidance. Switching isn't uncommon — some patients respond better to one than the other. Your provider will determine the appropriate starting dose for the new medication. There's usually no washout period needed, but don't manage this switch on your own. Read more: Semaglutide vs tirzepatide.

"Do I Need to Stop GLP-1 Before Surgery?"

Updated guidance (October 2024): Most patients can continue GLP-1 medications before elective surgery, according to multi-society clinical practice guidance from the American Society of Anesthesiologists (ASA) and others.

The key takeaway for seniors: Always inform your surgeon and anesthesiologist that you're on a GLP-1 medication. Work with your care team to determine the right approach for your specific situation rather than automatically stopping the medication.

Source: Multi-Society Clinical Practice Guidance, ASA et al. (October 29, 2024); published in Clinical Gastroenterology and Hepatology.

"What Happens to My Cost After the Introductory Pricing?"

This catches people off guard. Embody's first month is $99, but standard refills are $299/month — a $200 jump (flat plans from $199/month can soften it). MEDVi goes from $179 to $299, a $120 jump. Budget for the refill price, not the intro price. On the brand-name side, manufacturer savings cards have expiration dates and eligibility rules, and the Bridge's $50 copay runs only through December 2027 as currently authorized. Always ask: "What will I pay in month 3, month 6, and month 12?" before you start any program.

Shots vs. Pills vs. Gum: A Quick Comparison for Seniors

If you can handle a weekly injection — and most people can, the needle is tiny — the injectable versions currently offer stronger weight-loss results and more flexible timing. If needles are a hard no, you now have FDA-approved tablets (through your doctor or the Bridge) and a compounded gum (through Embody). Don't let the format question stop you from getting treatment you need.

Frequently Asked Questions: GLP-1 for Seniors

Your Next Step

If you've read this far, you've done more research than most people do before starting any medication. That's exactly the right approach for a health decision like this.

What to Bring to Your Doctor's Appointment

Whether you're starting with your primary care doctor or a telehealth provider, walking in prepared saves time and gets you better care. Print this list or screenshot it:

Before your appointment, have ready:

• A complete list of every medication you currently take (including dosages, over-the-counter meds, and supplements)
• Your most recent lab work (A1C, kidney function, lipid panel, thyroid) — if it's from the past 6 months, most providers can work with it
• Your current weight and height (for BMI calculation)
• A list of your diagnosed health conditions (diabetes, heart disease, high blood pressure, sleep apnea, kidney disease, etc.)
• Any history of pancreatitis, thyroid cancer, or eating disorders

Questions to ask your provider:

• "Based on my medications, are there any drug interactions I should know about with GLP-1 therapy?"
• "Do I qualify for the Medicare GLP-1 Bridge starting July 1 — and can we submit the prior authorization now?"
• "Do I need any lab work before starting?"
• "How will we monitor my muscle mass and bone health while I'm losing weight?"
• "What's my protein target, and can you refer me to a dietitian?"
• "If I'm on blood pressure medication, how often should we check whether I need a dose adjustment?"
• "What's the plan if I don't respond well to this medication?"

Here's the clearest path forward:

Step 1: If you have Medicare — check the Bridge first. If you have diabetes or heart disease, ask about coverage that exists today; if your goal is weight management and you meet the BMI criteria, ask your doctor to prepare the Bridge prior authorization now so you're ready July 1. You may be paying $50/month, not $300.

Step 2: If you don't have coverage, don't qualify, or want to start now — check your eligibility with a supervised telehealth provider. Here are your best options based on what matters most to you:

Each takes about 5 minutes and there's no commitment until a licensed clinician reviews your case and determines you're a good candidate.

Step 3: Whichever path you choose, make sure your provider screens for drug interactions, discusses protein and exercise, and monitors your progress — not just your weight, but your strength, your energy, and your labs.

This isn't about chasing a number on a scale. It's about your knees. Your heart. Your energy. Your independence. The clinical evidence says GLP-1 therapy can meaningfully improve all of these for seniors with obesity — and between Medicare's new $50 program and cash-pay starts under $100, you have more ways to access it affordably than ever before.

Sources cited in this article

1. Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT), NEJM 2023; 389:2221-2232
2. Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP-1), NEJM 2021
3. Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1), NEJM 2022
4. FDA prescribing information: Wegovy (2024, 2025 revisions), Ozempic, Zepbound, Mounjaro, Rybelsus, Foundayo
5. CMS — Medicare GLP-1 Bridge program pages, press release (May 2026), and FAQs (March 3, 2026). cms.gov
6. CMS — Medicare GLP-1 Bridge: Information for Medicare Beneficiaries (June 2026). cms.gov
7. KFF — "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge" (May 2026)
8. Medicare Rights Center — "GLP-1 Weight-Loss Drug Demonstration Begins July 2026" (June 4, 2026)
9. NPR — "Medicare to launch weight loss drug option in July with $50 copay" (May 6, 2026)
10. "Pharmacological Treatment of Obesity in Older Adults," PMC/Pharmacotherapy 2024
11. AACE/ACE Obesity Clinical Practice Guidelines
12. Novo Nordisk novoMEDLINK: Wegovy geriatric safety data
13. SELECT trial 4-year data (ECO 2024 presentation)
14. FDA — "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"
15. FDA — "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s," press release, March 3, 2026
16. FDA — Warning letter to MEDVi LLC, February 20, 2026
17. American Diabetes Association Standards of Care (2025)
18. Embody (joinem.co) — program pages, Terms & Conditions, Refund Policy, FAQ; pricing verified June 2026
19. MEDVi — program pages, pricing, Terms of Service; pricing verified June 2026
20. Multi-Society Clinical Practice Guidance, ASA et al. (October 29, 2024); Clinical Gastroenterology and Hepatology